ETEMA NEWSLETTER

Contact Us | Global Business Department | f-sales@jetema.com | Tel: +82 70 4337 6932 | www.jetema.com



#### Jetema successfully held the 1st Jetema Academic Meeting(JAM)

Jetema Academic Meeting

On May 22nd, Jetema announced the successful completion of the first JAM (Jetema Academic Meeting), a global academic online symposium. The 1st JAM was a symposium that led to online learning and in-depth discussions

about the minimal invasive aesthetic procedures using hyaluronic acid filler, polydioxanone lifting threads, and meso-solution, as well as the latest treatment methods using various combination of these products. More than 1,000 medical professionals in the field of cosmetic surgery from 41 countries around the world attended and participated in real-time Q&A and heated discussions. The theme of the first online symposium was "The Latest Discussion about Minimal Invasive Aesthetic Procedures", which was held in two sessions by six Korean speakers and an international moderator. The chairman and the moderator was Dr. Hema Sundaram, a world-renowned American dermatologist, who is a founder of dermatology, cosmetic and laser society in Maryland and Virginia and a visiting professor for the American Society for Dermatologic Surgery. Key speakers were people who lead the Korean aesthetic plastic surgery. (Seung Ho Han, a Professor at Ewha Womans University, Won Woo Choi, a Director of Wells Dermatology Clinic and Medical Spa, Doo Yeoul Chang, a Director of Change Clinic, Sang Ho Shin, a Director of Krismas Plastic Surgery, Won Lee, a Director of Yonsei E1 Plastic Surgery Clinic, and Ho Sung Choi, a Director of Piena Clinic.

These seven speakers participated and contributed to publicizing

Korea's high standard of cosmetic surgery to the globe. Jetema has been running web seminars (webinar) for countries such as Brazil, Russia, Greece, Bulgaria, and Indonesia since 2020, in a situation where it is difficult to exchange face-to-face meetings with cosmetic plastic surgeons around the world due to COVID-19. Lecture subjects were 'Essential Anatomy for Minimal Invasive Procedures', 'Lip injection and Marionette lines Corrections', 'Nasolabial Fold Correction using Filler and Threads', 'Using YouTube for your Hospital Marketing', 'Everything about Hyaluronidase', and 'Neck and Décolleté Rejuvenation using PN Mesosolution combined with Threads'. A survey taken after the symposium showed 100% of attendees are willing to attend Jetema's second symposium (2nd JAM). Jetema official said, "Through JAM, Jetema is not just trying to advertise and promote our product line, but moreover our goal is to convey and deliver the latest anatomical knowledge and new treatment methods that can be helpful in the field of treatment. We are doing our best for genuine academic exchanges, such as presenting and sharing solutions for side effects after the procedure." They also said, "JAM is not a one-time event, but is a regular global academic symposium. In our continuous JAM, we will continue to make efforts to contribute to the development of the global cosmetic plastic surgery field. In 2nd JAM, Jetema is planning to handle liaison with global doctors and try to share global view for co-development of east and west cosmetic plastic surgery field.

VOL. 04

## Interview with the Dr. Tamar Tsitsishvili - Cowgill

Dr. Tamar Tsitsishvili-Cowgill has been serving medical aesthetics for 20 years. She is a member of the International Mesotherapy Association in France, a member of the Georgian Aesthetic Association, a member of 'anti-age' medicine WOSIAM world organization, and a member of USA aesthetic medicine.

#### 1. What are the most popular filler indications in Georgia?

The most requested treatments in Georgia are nose correction, lip augmentation, and also oval correction using hyaluronic acid fillers.

2. What is the most important quality of filler when choosing a hyaluronic acid filler? When I choose a filler for my patients, I evaluate its quality. High quality means high purity of the final product, high viscoelasticity for optimum volumizing, safety, safety, and again safety. Also, the duration of the filler is important for patient satisfaction. But always the foremost importance is again safety at the moment and also in the future, which means even after the absorption of the hyaluronic acid, there must be no side effect and complications.

**3. What do you like about e.p.t.q.?** What I love about e.p.t.q. is its ultimate safety, immediate result, good integration in the dermis, smooth injection force, and after the absorption, the skin is ideally homogeneous.

From the range of e.p.t.q., my favorite is e.p.t.q. S300 lidocaine and S500 lidocaine. They both give excellent contouring for the nose, jawline, and midface. e.p.t.q. S100 lidocaine is good for refreshing skin.

Dr. Tamar Tsitsishvili-Cowgill



# e.p.t.q. Global Case Reviews

### **Forehead Face oval** Before Before Contouring Modeling e.p.t.q.S500 e.p.t.q.S500 lidocaine lidocaine Volume: 1mL Volume: 5mL After After **Midface** Nose Modeling Modeling e.p.t.q.S500 e.p.t.q.S500 lidocaine lidocaine Volume: 3ml Volume: 1ml Before Aft efore


Courtesy of Dr. Tamar Tsitsishvili-Cowgill

### e.p.t.q. introduced in Croatian magazine



AESTHETIC DERMATOLOGY NEWS

DR. NEVIA DELALLE: HOW DO I CHOOSE THE HIGHEST QUALITY FILLERS FOR PATIENTS?



e.p.t.q. filler and Dr. Nevia Delalle were introduced in ESTETICA, an online aesthetic magazine in Croatia.

### Interview with the Dr. Nevia Delalle

The average woman probably doesn't understand the rheology of filler. But for experts, it is precisely these details of rheology that are crucial in choosing the filler. We asked the most prominent dermatologist with exceptional experience in applying fillers, Dr. Nevia Delalle, to explain how she chooses fillers.

**1. What is your most important quality of filler?** As a long-time dermatologist with extensive experience with filler, I can say that the most important thing is safety, and everything else is minor. Side effects such as erythema, edema, hematoma, partly depend on us and partly on the sensitivity of the patient, but the filler itself must be flawless and safe, so we need to use a filler that is manufactured with the highest possible standards.

**2. What are those standards?** The most important standard in filler production is the crosslinking process. Chemical catalysts that are used in this process can be the main cause of many side effects. The amount of residual catalyst left in the finished product tells us about the quality and safety of the filler.

**3.** Any other safety tips? It is important to know what was previously injected if this is not the first filler application. I try to inject the same filler because I don't know what the possible reactions of the previous filler are with the one I inject. This is important for the patients to always know and have a written document of everything doctor injected because sometimes cross-reactions between previous injections and new one can be violent.

#### 4. Please share your e.p.t.q. experience and user tips with us.

I usually work with only a few types of fillers, and one of the newer fillers that meets my strict criteria is e.p.t.q. filler. Thanks to the elastic honeycomb structure, it is easily applied, modeled in the tissue, and at the same time tightens the skin. In doing so, it behaves naturally and adapts to mimic muscles. Clinical studies confirm its persistence, patient satisfaction, and safety. I use e.p.t.q. S100 for deep skin hydration. Due to its viscosity, I apply in the periocular region, lips, mentolabial region, and for soft correction of cheeks and forehead.

e.p.t.q. S300 is used for contouring, like the temporal region, and on the forehead. To add volume and lifting effect, I use S500 in a bolus.





Indication: Upper and lower cheeks Product: S500 Amount: 2mL



**Indication: Lip and perioral region** Product: S100 and S300 Amount: 3mL

Full article can be found at Dr. Nevia Delalle: Kako odabirem najkvalitetnije filere za pacijente? | | estetica.hr

# **Epiticon lifting thread**

# epiticon

# Simple yet effective Most Powerful thread

With increasing interest in skin elasticity and younger-looking features, the demand for skin lifting by removing and/or pulling up skin tissues has steadily increased, and thread lifting has become an indispensable procedure in the cosmetic plastic surgery market. In line with this trend in the cosmetic plastic surgery market, Jetema launched 'epiticon', a polydioxanone thread.

'epiticon' is gradually building a product pipeline with a fixed type (original) and bidirectional type (thin).



# POWERFUL

Strong Fixation and tensile force

# SAFE / EASY / EFFICIENT

Safe and simple procedure with thread with blunt cannula



#### epiticon Original

epiticon Original has repeating lifting and anchoring cogs, which gives strong fixation. Thanks to the structure, thread length is of no account, so it can be cut and used, and its efficacy is maintained even if it is broken due to external pressure. Also, the maximized distribution of force minimizes the formation of dimpling.

#### epiticon Thin

epiticon Thin is a very strong and thin bidirectional thread. epiticon Thin is #4-0 thick, but due to its special pressing technology, it exhibits a tensile strength of USP #2-0. The thinness increases the convenience of the procedure for the doctor and reduces the discomfort of foreign body sensations for the patient.





Indication: Jawline Lifting epiticon Original 2 lines/side

#### **Product Specifications**

Product	Cannula size / type	Thread length	USP
Original	18G / L type	90 mm	2-0
	19G / L type	60 mm	3-0
Thin	21G / L, A type	80 mm	4-0

## **Review of the newest science journal: Hip lifting threads**

# Gluteal Soft-Tissue Repositioning Using Polydioxane Threads

Won Lee, Young-Choon Jung and Eun-Jung Yang



**Background:** Buttock reshaping has recently gained popularity. Gluteal soft-tissue repositioning can be performed using polydioxane threads, followed by anthropometric measurements.

**Objective:** To evaluate the effectiveness of polydioxane threads (epiticon original) for noninvasive gluteal soft-tissue repositioning.

**Methods and Materials:** From February 2018 to August 2019, 27 women (mean age, 38.9 years; range, 26–65 years) underwent thread lifting. Multiple polydioxane threads (total, 24–30 threads for each buttock side, epiticon original) were used for gluteal soft-tissue repositioning. The treatment outcomes were based on comparisons of the preoperative and postoperative findings.





Figure 1. Schematic diagram of the sacrocutaneous and ischiocutaneous ligaments. Preoperative design of the entry points and estimated lines of thread insertion.



**Results:** The mean ratio of the upper and lower vertical proportions of the buttocks changed from 63:37 preoperatively to 55:45 postoperatively.

The mean projection angle of the upper portion decreased from 60.1° preoperatively to 54.3° postoperatively. Twenty-four patients (86%) were satisfied with the results up to 8 months postoperatively. One patient developed persistent pain (>1 month), and 4 patients showed skin dimpling, which resolved within 2 weeks after minimal massages. No hematomas, foreign body sensation, or thread protrusions were noted.

**Discussion:** Polydioxane threads could be an alternative, minimally invasive tool for buttock lifting. Our novel technique of repositioning the buttock soft tissue improved lifting and augmentation and provided a better buttock shape.

#### Table 1. Anthropometric Measurements of Buttock Repositioning.

Proportion, %	Preoperative	Postoperative
Upper	62.9 ± 4.9 (57–75)	54.7 ± 4.9 (50–70)
Lower	37.1 ± 4.9 (25–43)	45.3 ± 4.9 (30–50)

Data were analyzed by paired t-tests.



Figure 3. Schematic diagram of epiticon original





Figure 2. Anthropometric measurement of the buttock. Thread lifting was performed for a 46-year-old woman. A total of 60 threads were inserted (30 threads on each buttock). The preoperative (Left) and 3-months postoperative (Right) views.

### Jetema Activities

#### Established a pharmaceutical research center

Jetema established a research center specialized in pharmaceuticals at Pangyo Global R&D Center in order to strengthen and maximize expertise in the R&D. CEO said, "This is a project to respond flexibly to changes in the future market in the fields of pharmaceuticals, medical devices, and cosmo-therapeutics".



#### e.p.t.q. receives approval in Thailand

Jetema has announced their receipt of marketing approval from Thailand MOH for e.p.t.q. S100, S300, and S500 in May. e.p.t.q. is one of the earliest Korean HA filler to receive marketing approval in Thailand. e.p.t.q. will be officially launched in June 2021 and Jetema is very excited to enter the Thailand aesthetic market, which is one of the largest markets in Asia.



#### e.p.t.q. in SAM EXPO 2021 with Innovation Group

In the international exhibition of aesthetic medicine SAM EXPO 2021 held in Moscow, Russia, Oksana Pavlenko Ph.D. a scientific director of Innovation group, gave a lecture about "Full-face Correction using e.p.t.q. fillers".




#### e.p.t.q. global YouTube channel

Jetema has created a YouTube channel for e.p.t.q.

Click on eptq Global-YouTube

Channel consists of how to inject e.p.t.q. filler for all indications and other interesting contents of e.p.t.q.



#### Jetema THE TOXIN completed phase 1 clinical trial

JETEMA THE TOXIN is a botulinum toxin type A product for wrinkle improvement and is currently undergoing clinical trial.

On April 1st, the first phase clinical trial was completed to confirm the safety of the improvement of glabellar wrinkles of 100 units of JETEMA THE TOXIN (Clostridium botulinum toxin type A). After administration of the test drug (JTM201) and the reference drug (Botox<sup>®</sup>), JTM201 did not cause adverse drug reactions, so the results of safety assurance were announced.



Based on this, Jetema applied for IND (Investigational New Drug) for phase 3 clinical trials to the Ministry of Food and Drug Safety. It plans to assure the efficacy and safety of 306 patients for about 6 months. As soon as it is commercialized in Korea around the second half of 2022, it is scheduled to proceed with the approval process in major countries.